Press release
Glucagon-Like Peptide-1 Agonists Market Poised for Substantial Growth Through 2034 | DelveInsight
The latest comprehensive report by DelveInsight delivers detailed insights into the current and forecasted GLP-1 market size across 7MM, covering the period from 2020 to 2034. The glucagon market has witnessed transformative growth in recent years as GLP-1 agonists continue to demonstrate exceptional efficacy in managing type 2 diabetes and weight-related conditions. Key GLP-1 companies driving the growth in this landscape include AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk, among others.
According to DelveInsight's latest report, "Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast [https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", the Glucagon-like Peptide-1 (GLP-1) agonists market is projected to expand at a significant CAGR through 2034. The GLP-1 therapeutics market is primarily driven by the rising global diabetes epidemic, with approximately 537 million adults living with diabetes as of 2021. Type 2 diabetes mellitus accounts for over 85% of all diabetes cases, with about 1.4 million new cases diagnosed in the United States alone each year. The condition disproportionately affects older adults, with prevalence exceeding 25% among those over 65 years of age.
The GLP-1 epidemiology landscape continues to evolve as researchers gain deeper insights into the prevalence and distribution of type 2 diabetes and obesity across different demographic groups. DelveInsight's analysis indicates a substantial eligible patient population for GLP-1 therapy, with both diabetes and obesity rates projected to increase throughout the forecast period, further driving demand for effective therapeutic interventions.
Learn more about GLP-1 agonists patient trends by leveraging DelveInsight's expert analysis on GLP-1 epidemiological data [https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The report also discusses the Glucagon-like Peptide-1 agonists treatment landscape which encompasses various administration options, including injectable and oral formulations, providing patients and healthcare providers with flexible therapeutic approaches.
The current GLP-1 drug market is dominated by several key players and their approved medications. Regulatory bodies have approved multiple GLP-1 receptor agonists, including TRULICITY (Eli Lilly), BYETTA/BYDUREON (AstraZeneca), VICTOZA (Novo Nordisk), OZEMPIC/WEGOVY (Novo Nordisk), and MOUNJARO/ZEPBOUND (Eli Lilly and Company), among others . These medications have demonstrated efficacy in glycemic control and, in some cases, significant weight management benefits, further solidifying their position in the treatment paradigm for metabolic disorders.
The GLP-1 pipeline shows promising results, with several innovative candidates advancing through clinical development. Some of the therapies include orforglipron (Eli Lilly and Company), survodutide (Boehringer Ingelheim), danuglipron (Pfizer), and retatrutide (Eli Lilly and Company), among others. These emerging therapies aim to address current treatment gaps, improve efficacy profiles, and reduce side effects, potentially reshaping the competitive landscape in the coming years.
To uncover key insights into the rapidly growing GLP-1 agonists competitive dynamics and emerging innovations, visit the GLP-1 Market Insights [https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Recent developments highlight the expanding applications of GLP-1 agonists beyond traditional diabetes management. In July 2024, a significant milestone was reached when the MHRA approved semaglutide to reduce the risk of serious heart problems in obese or overweight adults, making it the first weight-loss drug approved in the UK as a preventative treatment for cardiovascular disease. Additionally, Roche announced promising early weight loss results from Phase I trials of its oral GLP-1 receptor agonist in July 2024.
Further, in November 2024, the FDA approved a generic version of BYETTA (AstraZeneca) by Amneal Pharmaceuticals. This was followed by the approval of a generic version of another GLP-1 receptor agonist, VICTOZA (Novo Nordisk), in December 2024, manufactured by Hikma Pharmaceuticals, suggesting a growing demand in the GLP-1 agonists landscape.
In conclusion, the Glucagon-like Peptide-1 agonists market is poised for significant growth through 2034, driven by the increasing prevalence of type 2 diabetes and obesity worldwide. With a robust pipeline of innovative therapies from leading pharmaceutical companies, the market is expected to witness transformative changes in treatment paradigms.
As new formulations and delivery methods emerge, patient outcomes are likely to improve, potentially expanding the applications of GLP-1 agonists beyond diabetes management. However, challenges such as pricing, reimbursement, and market access will continue to shape the competitive landscape. Stakeholders in the healthcare industry should closely monitor these developments to capitalize on the expanding opportunities in the GLP-1 therapeutics market.
Access DelveInsight's detailed analysis [https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr] to understand how advancements in drug delivery systems and expanding indications are revolutionizing diabetes and obesity management
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Executive Summary of GLP-1 Agonists
4.
Key Events
5.
GLP-1 Agonists Market Overview At A Glance
6.
Background And Overview
7.
Target Population
8.
GLP-1 Agonists Marketed Drugs
9.
GLP-1 Agonists Emerging Drugs
10.
GLP-1 Agonists: The 7MM Analysis
11.
GLP-1 Agonists Unmet Needs
12.
SWOT Analysis
13.
KOL Views
14.
GLP-1 Agonists Market Access and Reimbursement
15.
Appendix
16.
Delveinsight Capabilities
17.
Disclaimer
18.
About DelveInsight
Related Reports
Diabetes Pipeline Insight [https://www.delveinsight.com/report-store/diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Diabetes Pipeline Insight provides comprehensive insights about the Diabetes pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Diabetes companies, including vTv Therapeutics (VTVT), Tonghua Dongbao Pharmaceutical, Eli Lilly and Company (LLY), Celon Pharma (CLN), Sciwind Biosciences, AstraZeneca (AZN), Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, and Chong Kun Dang Pharmaceutical among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glucagonlike-peptide1-agonists-market-poised-for-substantial-growth-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glucagon-Like Peptide-1 Agonists Market Poised for Substantial Growth Through 2034 | DelveInsight here
News-ID: 3953976 • Views: …
More Releases from ABNewswire
Blue Ocean Life Brings Ocean-Inspired Calm, Resilience, and Freedom to Everyday …
Blue Ocean Life Company LLC spreads a message of healing, balance, and coastal calm through its mission-driven apparel and lifestyle brand. With designs like "Saltwater Heals Everything" and "Find Your Calm," the Cape Cod-based company blends style with purpose, reminding people of the restorative power of the ocean while addressing rising mental health challenges through lifestyle design.
CAPE COD, Mass. - Blue Ocean Life Company LLC is spreading a message of…
Third Hemisphere Strengthens Position as Leading Investment Communications Speci …
Jeremy Liddle [https://thirdhemisphere.agency/about-us] Third Hemisphere has established itself as a specialist in alternative investment communications, expanding capabilities across private credit, growth equity, and venture capital. The agency's regional positioning reflects the increasing sophistication of the Asia-Pacific investment landscape, where institutional allocators are diversifying beyond traditional public markets into private and alternative asset strategies.
The alternative investment environment in the region demands communications expertise that integrates financial understanding, Third Hemisphere, a full…
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure.
Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is…
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business.
KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus.
Each collection features 30 professionally produced instrumental tracks, available in both WAV…
More Releases for Insight
Europe Predictive Maintenance Market, Segmentation, Insight, Scope, & Insight by …
Europe Predictive Maintenance Market will project a CAGR of 40.10% during the forecast up to 2029.
Predictive maintenance is known to lead a huge increase in ROI. It can decline maintenance costs up to 25%-30%, decrease breakdowns to 70%-75%, and reduce downtime to 35%-45%. These services are being highly deployed as they save overall cost for enterprises.
Europe Predictive Maintenance Market was valued at USD 490.88 million in 2021 and is expected…
Returnable Transport Packaging Market, Segmentation, Insight, Scope, & Insight b …
Returnable Transport Packaging Market grows at a CAGR of 5.9% in the forecast period 2021-2028.
Market Analysis & Insights: Returnable Transport Packaging Market
Returnable transport packaging market will grow at a rate of 5.9% for the forecast period of 2021 to 2028. Rising reduction in cost of supply chain cycle and reduction of operational cost which acts as an essential factor driving the returnable transport packaging market.
Traditional methods of packaging that…
Next-Generation Firewall Market, Segmentation, Insight, Scope, & Insight by 2028 …
Next-Generation Firewall Market grows at a CAGR of 11.9% in the forecast period 2021-2028.
Market Analysis & Insights: Next-Generation Firewall Market
The next-generation firewall market is expected to witness market growth at a rate of 11.9% in the forecast period of 2021 to 2028. Data Bridge Market Research report on next-generation firewall market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing…
System Integration Market, Segmentation, Insight, Scope, & Insight by 2028.
System Integration Market grows at a CAGR of 10.67% in the forecast period 2022-2029.
System Integration Market Share Analysis
Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to…
Crypto Asset Management Market, Segmentation, Insight, Scope, & Insight by 2029.
Crypto Asset Management Market grows at a CAGR of 25.50% in the forecast period 2022-2029.
Market Analysis & Size: Crypto Asset Management Market
Cryptocurrency is one of the more exciting investing prospects to emerge in recent years. An increasing number of institutional investors and wealth managers who have never invested in cryptocurrencies are getting ready to do so in the upcoming year as their prices continue to rise. The global market…
Optical Waveguide Display Market, Segmentation, Insight, Scope, & Insight by 202 …
Optical Waveguide Display Market grows at a CAGR of 12.90% in the forecast period 2022-2029.
Market Analysis & Insights: Optical Waveguide Display Market
Augmented reality (AR) portable and wearable devices have emerged as one of the greatest technology in past few years. Optical waveguide technology has the best potential to enable the consumer-grade AR glasses owing to its appearance, mass production capability and optical performance. It is being considered an unparalleled choice…
